CRISPR Therapeutics (NASDAQ: CRSP) reported Q3 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $890 thousand versus the consensus estimate of $9.41 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.